Atrial Fibrillation Cycle Length Measured on Transesophageal Echocardiography

Atrial Fibrillation (AF) Cycle Length Measured on Transesophageal Echocardiography : a Feasible Parameter for Predicting the Recurrence of AF in Patients With AF Converted to Sinus Rhythm After DC Cardioversion

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03496272

Enrollment

100

Registered

2018-04-12

Start date

2017-01-01

Completion date

2021-06-30

Last updated

2018-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

Background: The atrial fibrillation cycle length (AFCL) measured by electrophysiologic study is well known parameter for the maintenance of sinus rhythm after DC cardioversion (DCCV) or ablation therapy. The aim of this study was to test whether a AFCL measured by transesophageal echocardiography (AFCLTEE) could predict the outcome after DCCV. Methods: In 100 consecutive patients with non-valvular AF, TEE will be performed within 6 hours before DCCV. The AFCLTEE was measured by averaging 10 sequential peak to peak intervals of atrial fibrillary waves seen in the pulsed wave Doppler image on the left atrial appendage. The primary endpoint was AF free survival rate at 6 months after DCCV.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* atrial fibrillation

Exclusion criteria

* moderate or severe mitral stenosis * prosthetic heart valve

Design outcomes

Primary

Measure	Time frame	Description
AF free survival rate at 6 months after DCCV	6 month	Atrial fibrillation free state at 6 months after direct current cardioversion

Countries

South Korea

Contacts

Primary ContactYong Hyun Park, MD

nadroj@pusan.ac.kr82-55-360-2363

Outcome results